首页> 外文期刊>Science >Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
【24h】

Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma

机译:染色质重塑基因ARID1A在卵巢透明细胞癌中的频繁突变。

获取原文
获取原文并翻译 | 示例
       

摘要

Ovarian clear cell carcinoma (OCCC) is an aggressive human cancer that is generally resistant to therapy. To explore the genetic origin of OCCC, we determined the exomic sequences of eight tumors after immunoaffinity purification of cancer cells. Through comparative analyses of normal cells from the same patients, we identified four genes that were mutated in at least two tumors. PIK3CA, which encodes a subunit of phosphatidylinositol-3 kinase, and KRAS, which encodes a well-known oncoprotein, had previously been implicated in OCCC. The other two mutated genes were previously unknown to be involved in OCCC: PPP2R1A encodes a regulatory subunit of serine/threonine phosphatase 2, and ARID1A encodes adenine-thymine (AT)-rich interactive domain-containing protein 1A, which participates in chromatin remodeling. The nature and pattern of the mutations suggest that PPP2R1A functions as an oncogene and ARID1A as a tumor-suppressor gene. In a total of 42 OCCCs, 7% had mutations in PPP2R1A and 57% had mutations in ARID1A. These results suggest that aberrant chromatin remodeling contributes to the pathogenesis of OCCC.
机译:卵巢透明细胞癌(OCCC)是一种侵略性人类癌症,通常对治疗有抵抗力。为了探索OCCC的遗传起源,我们确定了癌细胞免疫亲和纯化后的8个肿瘤的外显子序列。通过对来自同一患者的正常细胞的比较分析,我们确定了在至少两个肿瘤中突变的四个基因。以前曾在OCCC中涉及到PIK3CA(其编码磷脂酰肌醇3激酶的一个亚基)和KRAS(其编码众所周知的癌蛋白)。之前还不知道其他两个突变基因是否参与OCCC:PPP2R1A编码丝氨酸/苏氨酸磷酸酶2的调节亚基,而ARID1A编码富含腺嘌呤(AT)的含有相互作用域的蛋白质1A,该蛋白质参与染色质重塑。突变的性质和模式表明,PPP2R1A作为癌基因起作用,而ARID1A作为肿瘤抑制基因起作用。在总共42个OCCC中,有7%的PPP2R1A突变和57%的ARID1A突变。这些结果表明,异常的染色质重塑有助于OCCC的发病机理。

著录项

  • 来源
    《Science》 |2010年第6001期|p.228-231|共4页
  • 作者单位

    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center,Baltimore, MD 21231, USA;

    rnDepartment of Gynecology and Obstetrics and Oncology, Johns Hopkins Medical Institutes,Baltimore, MD 21231, USA;

    rnDepartment of Pathology, Oncology, Gynecology, and Obstetrics, Johns Hopkins Medical Institutes, Baltimore, MD 21231, USA;

    rnDepartment of Pathology,National Taiwan University College of Medicine, Taipei 100, Taiwan;

    Department of Gynecology and Obstetrics, Shimane University School of Medicine, Izumo, Shimane 6938501, Japan;

    rnDepartment of Pathology, Oncology, Gynecology, and Obstetrics, Johns Hopkins Medical Institutes, Baltimore, MD 21231, USA;

    rnDivision of Hematology/Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA 99095, USA;

    rnDivision of Hematology/Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA 99095, USA;

    rnLudwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center,Baltimore, MD 21231, USA;

    rnLudwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center,Baltimore, MD 21231, USA;

    rnLudwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center,Baltimore, MD 21231, USA;

    rnLudwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center,Baltimore, MD 21231, USA;

    rnLudwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center,Baltimore, MD 21231, USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:54:43

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号